Home > Cardiology > ACC 2019 > Vascular Medicine > Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients

Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ACC 2019
Trial
STOPDAPT-2
Outcomes of the STOPDAPT-2 trial show that 1 month of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy offers a net clinical benefit when it comes to ischaemic and bleeding events in comparison with 12 months of DAPT consisting of aspirin and clopidogrel after the implantation of cobalt-chromium everolimus-eluting stents [1]. STOPDAPT-2 was a Japanese study involving 89 centres and >3,000 patients. A total of 38% of these patients had acute coronary syndrome. Patients received DAPT for the first month (clopidogrel or prasugrel and aspirin); after that period, they were randomised to clopidogrel monotherapy or DAPT (clopidogrel and aspirin) through 1 year. The primary endpoint of the study was a composite of cardiovascular (CV) death, myocardial infarction (MI), definite stent thrombosis, stroke, or thrombolysis in myocardial infarction major/minor bleeding at 12 months. The results suggested clopidogrel monotherapy was superio...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on